Cooley Advises Underwriters on Eleven Biotherapeutics IPO

Reston, VA. – February 14, 2014 – Cooley LLP announced today that it advised the underwriters on the initial public offering of Eleven Biotherapeutics. A clinical-stage biopharmaceutical company, Eleven Biotherapeutics now trades on the NASDAQ Global Market under the symbol "EBIO."

Citigroup, Cowen and Company, LLC and Leerink Partners LLC acted as joint book-running managers for the offering.

The Cooley corporate and securities team advising the underwriters was led by partner Brent Siler and included partner Drew Williamson, special counsel Brian Leaf and associate Robert E. Jones. Critical support for the offering was provided by partner and chair of Cooley's healthcare and life sciences practice Drew Gantt, partner Natasha Leskovsek and associate David Sclar (regulatory); partner Bill Christiansen and associate Aaron Nudelman (intellectual property); and partner Susan Cooper Philpot (tax).

This offering follows Cooley's record year in 2013 for capital markets in which the firm advised on 60 public offerings, including 23 IPOs, raising more than $8.4 billion. Year-to-date in 2014, Cooley has advised on 20 public offerings, including 10 IPOs.

About Cooley LLP

Cooley's attorneys solve legal issues for entrepreneurs, investors, financial institutions and established companies. Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and bet-the-company litigation, often where innovation meets the law.

Cooley has more than 750 lawyers across 11 offices in the United States and China.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction, and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may have been generated with the assistance of artificial intelligence (AI) in accordance with our AI Principles, may be considered Attorney Advertising and is subject to our legal notices.